

REMARKS

Claims 1-23 were pending. Claims 1-23 are canceled without prejudice or disclaimer and Claims 24-43 are newly added. Claims 24-43 are pending and under examination.

Support for the amendments to the specification and for each of the new claims can be found in the claims and specification as originally filed. No new matter is added.

The amendments to the specification at page 1 merely correct the priority information for the subject application. Support for the priority of the subject application can be found in form PTO-1390 (Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission Under 35 U.S.C. 371) filed with the application. No new matter is added.

The amendment to the specification at page 8 merely corrects a typographical error. Specifically, the word “eosonophils” is corrected to “eosinophils”. No new matter is added.

The amendments to the specification at page 26 merely correct typographical errors. Specifically, the phrase “an DNA/RNA” is corrected to “a DNA/RNA” and the word “cyclohenyl” is corrected to “cyclohexenyl”. No new matter is added.

The amendments to the specification at page 26 merely clarify the sentence and correct typographical errors. The redundant phrase “a backbone” is deleted and the spelling of “olignucleotide” is corrected to “oligonucleotide”. No new matter is added.

Support for new Claim 24 can be found in originally filed Claim 1 and in the specification at page 103, lines 30-33 and Figure 18.

Support for new Claims 25-26 can be found in originally filed Claims 2 and 3 and at page 53, lines 12-14.

Support for new Claim 27 can be found at page 101, line 29 and Table 1.

Support for new Claim 28 can be found in originally filed Claim 4 and at page 101, lines 29-31 and in Figure 18.

Support for new Claim 29 can be found at page 103, lines 30-33.

Support for new Claim 30 can be found at page 104, lines 13-18.

Support for new Claim 31 can be found at page 98, lines 22-25.

Support for new Claim 32 can be found at page 17, lines 21-31 and page 101, lines 15-16.

Support for new Claim 33 can be found at page 8, lines 32-35.

Support for new Claim 34 can be found at page 101, lines 29-31 and in Table 1.

Support for new Claim 35 can be found at page 21, lines 1-4, page 101, lines 31-35 and in Table 1.

Support for new Claim 36 can be found at page 21, lines 4-6, page 101, lines 31-35 and in Table 1.

Support for new Claim 37 can be found at page 30, line 28 to page 34, line 31 and page 101, lines 31-35.

Support for new Claim 38 can be found at page 27, lines 3-17 and page 45.

Support for new Claim 39 can be found at page 31, lines 15-17, page 49, lines 12-35 and page 101, lines 31-35.

Support for new Claim 40 can be found at page 34, line 33 to page 39, line 2.

Support for new Claim 41 can be found at page 35, lines 3-5, page 101, lines 31-35.

Support for new Claim 42 can be found at page 49, lines 27-35 and page 101, lines 31-35.

Support for new Claim 43 can be found in originally filed Claim 1 and at page 98, lines 22-25, page 103, line 28 to page 104, line 12 and in Table 1.

Accordingly, no new matter has been added to the instant application and Applicants request entry of the claims into the record.

CONCLUSION

If any issues require clarification, the Examiner is invited to contact the undersigned at the telephone number provided below in order to expedite the resolution of such issues.

No fees are due for this Amendment. However, should any fees be deemed necessary, the Commissioner is hereby authorized to charge such fees to Deposit Account 50-0252 referencing case number ISIS-0852US.

Respectfully submitted,

Date: 10/22/08

Teresa Y. Liang
Teresa Y. Liang, Ph.D.
Registration No. 51,946

Isis Pharmaceuticals
1896 Rutherford Road
Carlsbad, CA 92008
Telephone: (760) 603-4601
Fax: (760) 603-3820